ADVISORY, March 15, 2007 (PRIME NEWSWIRE) --
What: Don M. Hardison, President and Chief Executive Officer of EXACT Sciences Corporation (EXAS), will preside over the closing bell. Where: NASDAQ MarketSite - 4 Times Square - 43rd & Broadway - Broadcast Studio When: Friday, March 16, 2007, at 4 p.m. EST Contacts: Theresa McNeely, firstname.lastname@example.org; 508.523.9511 NASDAQ MarketSite: Jolene Libretto; 646.441.5220; 347.219.9539 Jolene.Libretto@NASDAQ.com
The closing bell is available from 3:50 p.m. EST to 4:05 p.m. EST on uplink IA-6 C-band/transponder 17. The downlink frequency is 4040 Vertical; Audio 6.2-6.8. The feed can also be found on Waterfront fiber 1623. If you have any questions, please contact Jolene Libretto at 646.441.5220.
A live Webcast of the NASDAQ Closing Bell will be available at: http://www.nasdaq.com/reference/marketsite_about.stm
To obtain a hi-resolution photograph of the Market Close, please go to http://www.nasdaq.com/reference/marketsite_events.stm and click on the market close of your choice.
About EXACT Sciences Corporation (EXAS):
EXACT Sciences Corporation is applying advances in genomics to facilitate the early detection of common cancers. The Company's stool-based, DNA technology offers the most accurate, non-invasive diagnostic available for the detection of colorectal cancer (CRC). CRC is the 2nd leading cause of cancer deaths and according to the American Cancer Society's journal, screening has been shown to have the biggest impact on improving mortality, over treatment and behavior modification. Despite this, more than half of the 87 million people over the age of 50 who should be adequately screened are not, and this rate increases by approximately four million each year.
EXACT Sciences has a commercial partnership with Laboratory Corporation of America (LabCorp.), which offers a simple, non-invasive CRC screening test based on EXACT's proprietary technologies. EXACT Sciences also aims to exploit new opportunities within CRC, such as staging and monitoring, and pursue new opportunities in other cancers.